Instrument Inactif

Communiqués Apexigen, Inc.

Actions

APGN

US03759B1026

Recherche biotechnologique et médicale

Communiqués

10/08/23	APEXIGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN	BU
03/06/23	Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting	AQ
31/05/23	APEXIGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN	BU
24/05/23	Pyxis Oncology to Acquire Apexigen	AQ
12/04/23	APEXIGEN, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
27/02/23	APEXIGEN, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
27/02/23	Apexigen Announces Review of Strategic Alternatives and Restructuring	AQ
22/02/23	APEXIGEN, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
14/02/23	APEXIGEN, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
01/02/23	APEXIGEN, INC. : Unregistered Sale of Equity Securities (form 8-K)	AQ
25/01/23	APEXIGEN, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
24/01/23	Apexigen Announces Approximately $2.8 Million Private Placement Financing	AQ
19/01/23	Apexigen Announces New Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, at ASCO Gastrointestinal Cancers Symposium 2023	AQ
15/11/22	Apexigen Reports Third Quarter 2022 Financial Results and Provides Business Update	AQ
14/11/22	Apexigen Announces Positive Interim Results from Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Doxorubicin in Patients with Liposarcoma	AQ
11/11/22	Apexigen Announces New Data from a Phase 1/2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with First-Line Metastatic Melanoma at the SITC 2022 Annual Meeting	AQ
10/09/22	Apexigen Presents New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022	AQ
07/09/22	Apexigen to Participate in the H.C. Wainwright 24th Annual Global Investment Conference	AQ
05/09/22	Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022	AQ
04/08/22	Apexigen to Participate in the 2022 Wedbush PacGrow Healthcare Conference	AQ